triflusal has been researched along with clopidogrel in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borja, J | 1 |
| Weinberger, J | 1 |
| Ezekowitz, MD; Jamieson, DG; Parekh, A | 1 |
| Acciarresi, M; Caso, V; Paciaroni, M; Pezzella, FR; Santalucia, P | 1 |
| Kang, W; Kwon, KI; Lee, BY; Park, S; Yeul Ma, J; Yoon, YR; Yun, HY | 1 |
| Ahn, SH; Han, SW; Kim, YJ; Kim, YN; Lee, KY; Oh, SH; Seo, WK; Yu, S | 1 |
| Colás, C; Cubero, JL; Millán, P; Simó Sánchez, B | 1 |
| de Abajo, FJ; García-Rodríguez, LA; Gil, M; Montoya, H; Rodríguez-Martín, S; Rodríguez-Miguel, A | 1 |
3 review(s) available for triflusal and clopidogrel
| Article | Year |
|---|---|
Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Salicylates; Stroke; Ticlopidine; Warfarin | 2005 |
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Stroke; Ticlopidine | 2005 |
Antiplatelet treatment in primary and secondary stroke prevention in women.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; Naphthalenes; Platelet Aggregation Inhibitors; Primary Prevention; Propionates; Salicylates; Secondary Prevention; Sex Factors; Stroke; Ticlopidine | 2012 |
1 trial(s) available for triflusal and clopidogrel
| Article | Year |
|---|---|
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Topics: Brain Ischemia; Cerebral Hemorrhage; Chemoprevention; Clopidogrel; Cytochrome P-450 CYP2C19; Follow-Up Studies; Genotype; Humans; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Recurrence; Salicylates; Secondary Prevention; Single-Blind Method; Stroke; Ticlopidine; Treatment Outcome | 2016 |
4 other study(ies) available for triflusal and clopidogrel
| Article | Year |
|---|---|
Oral antiplatelet therapy.
Topics: Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Salicylates; Ticlopidine | 2005 |
Semi-mechanistic modelling and simulation of inhibition of platelet aggregation by antiplatelet agents.
Topics: Adult; Blood Platelets; Cilostazol; Clopidogrel; Half-Life; Humans; Models, Theoretical; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; Salicylates; Tetrazoles; Ticlopidine; Young Adult | 2014 |
Aspirin desensitization in patients with coronary artery disease: Cost savings.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost Savings; Desensitization, Immunologic; Drug Hypersensitivity; Drug Substitution; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Salicylates; Ticlopidine | 2017 |
Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Colorectal Neoplasms; Dual Anti-Platelet Therapy; Female; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Protective Factors; Risk Reduction Behavior; Salicylates; Spain | 2019 |